

1 **Impact of COVID-19 vaccine doses and viral waves on inflammatory and**  
2 **immunological responses to COVID-19 infections in India**

3 Kamal Kant Sharma<sup>1</sup>, Uttara Partap<sup>2</sup>, Yogesh Marathe<sup>1</sup>, Sanaa Shaikh<sup>1</sup>, Pradeep D'Costa<sup>3</sup>,  
4 Gaurav Gupta<sup>4</sup>, Molin Wang<sup>5,6</sup>, Wafaie W Fawzi<sup>2,5,7</sup>, Kevin C Kain<sup>8</sup>, Nerges Mistry<sup>1</sup>, Yatin  
5 Dholakia<sup>1</sup>

6 **Affiliations:**

7 <sup>1</sup>The Foundation for Medical Research, Mumbai, India

8 <sup>2</sup>Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston,  
9 Massachusetts, USA

10 <sup>3</sup>King Edward Memorial Hospital and Research Centre, Pune, India

11 <sup>4</sup>Saifee Hospital, Mumbai, India

12 <sup>5</sup>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts,  
13 USA

14 <sup>6</sup>Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA

15 <sup>7</sup>Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA

16 <sup>8</sup>Department of Medicine, University of Toronto and University Health Network, Toronto, Ontario,  
17 Canada

18

19 **Corresponding author:**

20

Dr. Yatin Dholakia

The Foundation for Medical Research

Dr. Kantilal J. Sheth Memorial Building

84-A, R.G. Thadani Marg

Worli, Mumbai 400 018, India

[yatindholakia@gmail.com](mailto:yatindholakia@gmail.com), Contact Number: +91 22 2493 4989

21 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

22 **Abstract:**

23 **Background:** Investigation of the effect of SARS-CoV-2 variants and COVID-19 vaccination on  
24 inflammatory and immune response to SARS-CoV-2 infection is limited in South Asia.

25 **Objectives:** We aimed to examine the impact of COVID-19 vaccination and waves of COVID-  
26 19 on inflammatory and immunological biomarkers among COVID-19 patients in India.

27 **Methods:** This cross-sectional analysis used baseline data from a randomized controlled trial  
28 of vitamin D and zinc during COVID-19 infection in India (N=181). Blood samples and data  
29 regarding vaccination doses were collected. The second (Delta) or third (Omicron) wave was  
30 determined by date of enrolment. Mixed effects linear regression with robust standard  
31 errors was used to examine associations between COVID-19 vaccination dose or wave at  
32 enrolment and C-Reactive Protein (CRP), ferritin, lactate dehydrogenase (LDH), D-dimer,  
33 interleukin-6 (IL-6), angiotensin-2 (Ang-2), soluble triggering receptor expressed on myeloid  
34 cells-1 (sTREM-1), immunoglobulin G (IgG) and immunoglobulin M (IgM).

35 **Results:** Compared to no vaccination, full vaccination was associated with lower LDH  
36 ( $P<0.001$ ), D-dimer ( $P=0.521$ ) and Ang-2 ( $P=0.046$ ), and higher IgG levels ( $P<0.001$ ). Partial  
37 vaccination was associated with lower IL-6 ( $P=0.040$ ) and higher IgG ( $P<0.001$ ). Enrolment  
38 during the third wave was associated with lower IL-6 ( $P<0.001$ ), CRP ( $P=0.056$ ), IgM  
39 ( $P=0.013$ ), and IgG ( $P<0.001$ ), but higher D-dimer levels ( $P<0.001$ ).

40 **Conclusions:** COVID-19 vaccination status and SARS-CoV-2 variant influence the  
41 inflammatory and immunologic response during SARS-CoV-2 infection, contributing to the  
42 severity of clinical presentation.

43 **Keywords:** COVID-19, vaccine, variants, inflammation, immunology, biomarkers

44 Tables: 4, Figures: 0

45 Word count: 3762 (Introduction: 420, Discussion: 1346), Abstract: 223

46 **Competing interests:**

47 All authors declare no conflicts of interest.

48 **Registration:**

49 Clinical Trial Registry of India (CTRI): CTRI/2021/04/032593

50 (<https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NTQ1MTA=&Enc=&userName=CTRI>

51 /2021/04/032593)

52 **Ethical approval:**

53 This study was conducted in accordance with the Declaration of Helsinki, and informed

54 written consent was taken from study participants. Ethical approval was obtained from the

55 Institutional Review Board of the Harvard T.H. Chan School of Public Health (Protocol No.

56 IRB20-1425), the University Health Network Research Ethics Board (20-5775), the

57 Institutional Research Ethics Committee of the Foundation for Medical Research (IREC No.

58 FMR/IREC/C19/02/2020), the Institutional Review Board of Saifee Hospital (Project No.

59 EC/008/2020) and the KEM Hospital Research Centre Ethics Committee (KEMHRC ID No.

60 2027).

61 **Author contributions:**

62 KKS, UP, WWF, KCK, YD, and NM conceptualized the study along with YM, SS, PD, GG and

63 MW. KKS, YD, YM, SS, PD and GG were involved in data acquisition, and in study monitoring

64 along with KCK, WWF, NM and UP. MW provided statistical expertise. KKS and UP analysed

65 the data, KKS drafted the first draft of manuscript, and all authors reviewed and critically

66 revised the draft and approved the final manuscript.

67

## 68 Introduction

69 COVID-19 infection is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-  
70 CoV-2), a major global health concern of the 21st century, and has affected more than 609  
71 million people and caused over 6.5 million deaths worldwide.<sup>[1]</sup> The ability of SARS-CoV-2  
72 viruses to undergo frequent and random mutations may result in the development of highly  
73 contagious and lethal variants, and this has extended the COVID-19 pandemic through  
74 multiple waves of infection.<sup>[1]</sup>

75 The progression of COVID-19 infection is associated with altered clinical manifestations and  
76 changes in the level of related inflammatory and immunological biomarkers. Innate immune  
77 responses, coagulation, and the initiation of pro-inflammatory responses are common  
78 pathways to counteract infectious agents, which may result in increased circulating levels of  
79 acute phase proteins such as C-reactive protein (CRP), ferritin, and D-Dimer. In particularly  
80 acute cases, the proliferation of the virus in the host cell and its rapid spread in other cells  
81 results in a cytokine storm, which is considered a critical condition.<sup>[2]</sup> The profile of human  
82 immune response, transmission ability, laboratory characteristics, and antigenicity of the  
83 virus depends at least partially on the COVID-19 virus variant.<sup>[3,4]</sup> While differences in  
84 symptoms have been noted,<sup>[5]</sup> there are limited data available on inflammatory and  
85 immunological responses to different SARS-CoV-2 variants, particularly from South Asian  
86 populations.

87 Protective immunity through vaccines was paramount to reducing the severity of COVID-19  
88 disease and breaking the chain of transmission. India also scaled up its domestic vaccine  
89 research and development program for the launch of the vaccination drive in the country by  
90 January 2021 and has achieved over 2 billion vaccinations so far.<sup>[6]</sup> Around 921 million

91 people had their first dose of the COVID-19 vaccine in India, 863 million were fully  
92 vaccinated (2 doses), and around 139 million received their precautionary dose by  
93 September 2022.<sup>[7]</sup> It has been observed that vaccination and its doses directly impact the  
94 inflammatory and antibody response to SARS-CoV-2 infection.<sup>[8,9]</sup> However, evidence  
95 regarding the effect of COVID-19 vaccination on the inflammatory and immunological  
96 response among newly-infected patients remains limited, particularly from lower- and  
97 middle-income populations such as those in South Asia.<sup>[10]</sup>

98 Few data have been reported on a comprehensive range of inflammatory and  
99 immunological markers by COVID-19 vaccination doses and second versus third waves of  
100 the COVID-19 pandemic (which roughly correspond to two distinct SARS-CoV-2 variants –  
101 Delta and Omicron respectively) from COVID-19 patients, particularly in India. In this study,  
102 we aimed to determine the association between COVID-19 vaccination doses and waves of  
103 COVID-19, and a set of inflammatory and immunological biomarkers, among SARS-CoV-2-  
104 infected patients in Maharashtra, India.

105

## 106 **Materials and Methods**

### 107 Study procedures

108 This analysis uses baseline data from a randomized controlled trial aiming to evaluate the  
109 effects of vitamin D and zinc supplementation on COVID-19 outcomes in Maharashtra, India  
110 (ClinicalTrials.gov registration: NCT04641195).<sup>[11]</sup> From April 2021 to February 2022,  
111 hospitalized or home-isolated COVID-19 patients aged  $\geq 18$  years with a positive RT-PCR or  
112 rapid antigen test and with mild to moderate symptoms were enrolled from two study sites:  
113 King Edward Memorial (KEM) Hospital and Research Centre, Pune, and Saifee Hospital,  
114 Mumbai.

115 Details regarding study procedures have been outlined previously,<sup>[11]</sup> baseline procedures  
116 are briefly described as follows. At enrolment, background information, medical history, and  
117 clinical symptoms were obtained and clinical assessment was conducted along with the  
118 collection of blood samples for routine laboratory investigations and study of specific  
119 inflammatory and immunological biomarkers. In addition, participants were asked about  
120 details of their COVID-19 vaccination status at baseline and during successive follow-ups.  
121 Routine blood investigation included testing of CRP, lactate dehydrogenase (LDH), serum  
122 ferritin, and D-dimer. This was performed at the respective hospital sites, which were  
123 accredited by the National Accreditation Board for Testing and Calibration  
124 Laboratories (NABL). All COVID-19 treatment, such as medications, was delivered by  
125 clinicians independently of the study, guided by the national treatment recommendations  
126 for COVID-19 at the time.<sup>[12]</sup>

127 Testing of other plasma biomarkers including angiopoietin-2 (Ang2), interleukin-6 (IL-6),  
128 soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), immunoglobulin G (IgG),

129 and immunoglobulin M (IgM) were conducted at the coordinating institute, The Foundation  
130 for Medical Research (FMR). Blood samples collected were processed at hospital sites for  
131 plasma, and the centrifuged matrix was transported to FMR adhering to the transportation  
132 regulations provided by the Government of India (GOI) for COVID-19 samples.<sup>[13]</sup> Aliquots of  
133 plasma were prepared for further testing and stored at -20°C. The concentration of  
134 biomarkers was quantified using sandwich enzyme-linked immunosorbent assay (ELISA),  
135 was performed according to the manufacturer's instructions; Thermofisher Invitrogen, USA  
136 (IL-6, Ang-2, sTREM-1) and RayBiotech, USA (IgG and IgM) and readings were observed at  
137 450 nm. Due to issues with the sample kit, sTREM-1 assays were performed only for a  
138 subset of 48 participants. To ensure accurate results, the samples were run in triplicates.

#### 139 Variables of interest

140 Exposures of interest were COVID-19 vaccination status and wave during which the  
141 participant was enrolled. Participants were categorized based on their COVID-19 vaccination  
142 doses received till the day of enrolment. Participants with no COVID-19 vaccine were  
143 grouped as unvaccinated, those with one dose were partially vaccinated, and those who  
144 received second dose and/or the final third (precautionary or booster) dose were  
145 categorized as fully vaccinated. Participants were enrolled across two waves of the COVID-  
146 19 pandemic in India. These waves were defined as wave 2 (predominantly Delta; enrolled  
147 from the start of the study in April 2021 to 15<sup>th</sup> December 2021), and wave 3  
148 (predominantly Omicron; enrolled from 21<sup>st</sup> December 2021, onwards – no participants  
149 were enrolled between 15<sup>th</sup>-21<sup>st</sup> December 2021).<sup>[14]</sup>

150 Outcomes of interest were the following inflammatory and immunological biomarkers:  
151 serum CRP, LDH, and ferritin, plasma D dimer, IL-6, Ang2, sTREM-1, IgG, and IgM. As part of

152 the analysis, we considered other potentially important participant characteristics including  
153 sex, age, education, health behaviour (smoking and alcohol consumption), pre-existing  
154 medical conditions, COVID-19 medication, body mass index (BMI), COVID-19 vaccine type,  
155 median number of days with symptoms and median days since last vaccine dose before  
156 enrolment.

### 157 Statistical analysis

158 First, baseline demographic, clinical, health behaviour, COVID-19 medication, and  
159 anthropometric characteristics were compared across the two exposures of interest: 1)  
160 COVID-19 vaccination and 2) COVID-19 waves. Differences between groups were examined  
161 by Pearson's Chi-squared tests or Fisher's exact tests (comparisons with cell counts <5) for  
162 categorical variables, and Wilcoxon rank sum tests or Kruskal Wallis tests (comparisons  
163 across >2 groups) for continuous variables. We also examined median biomarker levels  
164 across the two exposures of interest, testing for differences across groups using Wilcoxon  
165 rank sum tests or Kruskal Wallis tests, as described above.

166 Following this, effects of the exposures of interest on each outcome were modelled using  
167 mixed-effects linear regression with robust standard errors. Models were adjusted for the  
168 other exposure (either COVID-19 vaccination or wave), and for age, sex, health behaviour  
169 (smoking and alcohol consumption), pre-existing medical conditions, COVID-19 medication,  
170 BMI, COVID-19 vaccine type, and median number of days with symptoms and were  
171 additionally adjusted for clustering at the hospital site level. Although we also initially  
172 included days since last vaccination in regression models, this variable was dropped due to  
173 collinearity with the COVID-19 vaccination variable. Missing observations for covariates



174 were minimal (maximum: 2 participants [1.1%] for any covariate) and we assumed these  
175 were missing completely at random. We used the missing indicator method to handle  
176 missing data in regression models. All analyses were performed using STATA, version 14.1  
177 (StataCorp, Texas).

## 178 Ethics

179 The procedures followed in this study were in accordance with the ethical standards of all  
180 responsible ethical committees listed below, and with the Declaration of Helsinki, and  
181 informed written consent was taken from study participants. Ethical approval was obtained  
182 from the Institutional Review Board of the Harvard T.H. Chan School of Public Health  
183 (Protocol No. IRB20-1425), the University Health Network Research Ethics Board (20-5775),  
184 the Institutional Research Ethics Committee of the Foundation for Medical Research (IREC  
185 No. FMR/IREC/C19/02/2020), the Institutional Review Board of Saifee Hospital (Project No.  
186 EC/008/2020) and the KEM Hospital Research Centre Ethics Committee (KEMHRC ID No.  
187 2027). The trial is registered on ClinicalTrials.gov: NCT04641195, and Clinical Trial Registry of  
188 India (CTRI): CTRI/2021/04/032593. Health Ministry Steering Committee (HSMC) - GOI  
189 endorsement was received before the commencement of the study.

## 190 **Results**

### 191 **Overall baseline and clinical characteristics of the enrolled participants**

192 Total 181 COVID-19 patients were included in the study. The mean (SD) age of the study  
193 participants was 47 (15.7) years, and the range was 18-87 years. One-fourth of participants  
194 (24.8%) were 60 years of age or older. The proportion of male participants was 51.3%, and  
195 91.8% of participants had received secondary or higher-level education. Around 62% of  
196 participants were overweight or obese (30.9% in each category), only 6 individuals (3.3%)  
197 were underweight and a normal BMI was found in 34.8% participants. The median  
198 (interquartile range [IQR]) number of days with symptoms before enrolment was 3 days (2-  
199 4). 39.7% of participants reported comorbidities such as hypertension (24.8%), diabetes  
200 (20.9%), and cardiovascular disease (7.7%), and 19.8% of participants were on any COVID-19  
201 medications. Among the antiviral medications, Remdesivir was used the most frequently  
202 (12.2%) (Table 1).

### 203 **Baseline characteristics of the enrolled participants across exposure variables (vaccination** 204 **status and waves of COVID-19 pandemic in India)**

205 At the time of enrolment, one-fifth (19.9%) of individuals were unvaccinated, 13.3% had  
206 their first dose of COVID-19 vaccine, and 51.9% patients enrolled were fully vaccinated with  
207 two or three doses; 14.9% did not provide information on their vaccination status. The  
208 median days since last vaccine dose before enrolment was 126 days (IQR: 51-216). Fifty-  
209 eight percent individuals received COVISHIELD vaccine by AstraZeneca and Serum Institute  
210 of India, 7.1% received COVAXIN (Bharat Biotech) which was approved and introduced later,  
211 19.9% were unvaccinated at the time of enrolment, and rest around 15% did not provide  
212 their vaccination details (Table 1).

213 A greater proportion of unvaccinated and fully vaccinated individuals was male ( $P=0.049$ ).  
214 Additionally, a greater proportion of partially vaccinated individuals was in 30-44 years age  
215 group ( $P=0.008$ ), had graduate education ( $P=0.006$ ), was enrolled during the second wave  
216 ( $P<0.001$ ), and was using any COVID-19 medications ( $P=0.061$ ). Full vaccination was  
217 common in older participants who were more than 44 years, and among those who  
218 reported hypertension ( $P=0.023$ ), any pre-existing conditions, and obesity. The median days  
219 from last dose before enrolment in partially vaccinated participants was 61 days (IQR: 31-  
220 92) while it was 167 ([range 77-241] days for the fully vaccinated group ( $P<0.001$ )) (Table 1).  
221 Most (66.3%) of the study participants were enrolled during the second wave. A larger  
222 proportion of participants who enrolled in the second wave were aged 30-44 years  
223 ( $P=0.381$ ), and had normal BMI compared to third wave participants ( $P=0.019$ ). All  
224 participants enrolled in the third wave had secondary or higher education whereas about  
225 one tenth of those enrolled in the second wave had primary or less education ( $P=0.004$ ).  
226 Close to half (46%) of participants enrolled in the third wave were obese, compared with  
227 23.3% of participants enrolled in the second wave (Table 1).

### 228 **Levels of inflammatory and immunological biomarkers of COVID-19 infected participants** 229 **across vaccination status and waves of COVID-19 (unadjusted analyses)**

230 We first compared unadjusted median biomarker levels across vaccination status at  
231 enrolment and the COVID-19 wave in which the participants were enrolled. The unadjusted  
232 median CRP, LDH, ferritin, D-dimer and IL-6 levels were lower in fully and partially  
233 vaccinated groups as compared to the unvaccinated group ( $P<0.001$  for LDH and IL-6, and  $P=$   
234  $0.005$  for ferritin). The unadjusted levels of other inflammatory markers Ang-2 and sTREM-1  
235 were higher in both vaccinated groups than unvaccinated group, but not significant

236 ( $P=0.454$  and  $P=0.977$  respectively). Unadjusted IgG levels were significantly elevated in  
237 vaccinated groups as compared to the unvaccinated group especially in partially vaccinated  
238 people ( $P=0.009$ ), while unadjusted IgM levels were also notably high in partially vaccinated  
239 group and lower in fully vaccinated people ( $P=0.014$ ) (Table 2).

240 The study participants enrolled in the second wave had a higher median level of unadjusted  
241 CRP, LDH, ferritin, and IL-6 compared to individuals enrolled in the third wave ( $P<0.05$  for  
242 all). These participants also had lower unadjusted median D-dimer levels, though this was  
243 not significant ( $P=0.155$ ). Furthermore, unadjusted plasma levels of IgM and IgG antibodies  
244 were significantly lower in the third wave compared with second wave participants ( $P<0.001$   
245 and  $P=0.019$  respectively) (Table 2).

#### 246 **Regression analysis of effect of vaccination status and wave of COVID-19 pandemic on** 247 **inflammatory and immunological biomarkers (adjusted analyses)**

248 In fully-adjusted multivariable regression models, full vaccination (but not partial  
249 vaccination) was associated with lower LDH and Ang-2; LDH ( $\beta$ : -77.4, 95% CI: -89.3 – -65.4,  
250  $P<0.001$ ) and Ang-2 ( $\beta$ : -61.0, 95%CI: -121.0 – -1.0,  $P=0.046$ ) respectively. Full vaccination  
251 was also associated with lower D-dimer levels, but the association did not reach statistical  
252 significance ( $\beta$ : -248.9, 95% CI:-1,009.4 – 511.7,  $P=0.521$ ). Furthermore, partial and full  
253 vaccination was associated with lower IL-6 levels as compared to no vaccination, with  
254 similar magnitudes of difference for both groups but significant associations only for the  
255 partially vaccinated group ( $\beta$ : -41.8, 95% CI: -81.7 – -1.9,  $P=0.040$ ). In a subset of the cohort,  
256 in fully vaccinated participants had higher sTREM-1 levels ( $\beta$ :72.6, 95% CI: 70.6–74.5,  
257  $P<0.001$ ) (Table 3).

258 Although not significant, decreasing trends in CRP in partially vaccinated ( $\beta$ : -26.1, 95% CI: -  
259 102.1 – 50.0,  $P=0.502$ ) and fully vaccinated individuals ( $\beta$ : -28.5, 95% CI: -88.0 – 30.9,  
260  $P=0.347$ ) were observed, similarly decreasing ferritin levels in partial and fully vaccinated  
261 participants were also noticed ( $\beta$ : -38.7, 95% CI: -439.6– 362.2,  $P=0.850$  and  $\beta$ : -177.4, 95%  
262 CI: -691.3 – 336.5,  $P=0.499$  respectively) (Table 3).

263 Significant associations between partial and full vaccination and elevated IgG were detected  
264 ( $\beta$ : 61.5, 95% CI: 48.9 – 74.1,  $P<0.001$ , and  $\beta$ : 62.2, 95% CI: 56.7 – 67.6,  $P<0.001$   
265 respectively). Estimates suggested increased levels of IgM associated with partial  
266 vaccination. However, these estimates of increase were not significant, and were also not  
267 statistically different from estimates for fully-vaccinated individuals, with fully overlapping  
268 confidence intervals (Table 3).

269 Additionally, in these fully-adjusted analyses, enrolment in the third wave was associated  
270 with significantly lower IL-6 ( $\beta$ : -12.0, 95% CI: -12.6 – -11.4,  $P<0.001$ ), and CRP which was  
271 borderline significant ( $\beta$ : -21.7, 95% CI: -44.0 – 0.6,  $P= 0.056$ ). On the other hand, higher D-  
272 dimer values were significantly associated with enrolment in third-wave ( $\beta$ : 322.5, 95% CI:  
273 80.9 – 564.2,  $P=0.009$ ). Other inflammatory markers including ferritin, LDH, and Ang-2 levels  
274 were also lower in third-wave versus second-wave participants, but differences in these  
275 biomarkers were not significant (Table 4).

276 Significant lower IgG and IgM were associated with enrolment in the third wave as  
277 compared to second-wave; IgM ( $\beta$ : -23.6, 95% CI: -42.3 – -4.9,  $P= 0.013$ ) and IgG ( $\beta$ : -77.6,  
278 95% CI: -99.4 – -55.8,  $P<0.001$ ) (Table 4).

279

## 280 Discussion

281 In this study, we found that levels of inflammatory markers, particularly LDH and Ang-2  
282 were significantly lower in fully vaccinated participants compared to unvaccinated  
283 participants with COVID-19. Furthermore, we observed some evidence of lower IL-6 levels in  
284 both partially and fully vaccinated participants, and substantially elevated IgG levels in both  
285 partially and fully vaccinated participants. We also found that infection during the third  
286 wave was associated with lower CRP, IL-6, and IgG levels, and higher D-Dimer levels.

287 Inflammation is a defence mechanism that is activated by a coordinated signalling pathway,  
288 and also regulates inflammatory mediator levels in host tissue cells and inflammatory cells  
289 recruited from the blood.<sup>[15]</sup> Previous studies have shown that vaccinated patients have  
290 reduced severity of COVID-19 disease compared to unvaccinated patients, and individuals  
291 with different vaccination doses have variable immune-inflammatory characteristics  
292 including the existence of higher neutralizing antibodies response and lower inflammatory  
293 markers.<sup>[16,17]</sup>

294 CRP LDH, ferritin, D-dimer, and IL-6 are inflammatory markers explored commonly in COVID-  
295 19 and other research studies. However, evidence on the association between COVID-19  
296 vaccination and variants and other inflammatory markers such as Ang-2 and sTREM-1, as  
297 performed in our study, is scarce – we were unable to find any relevant studies during our  
298 search of the literature on these associations. Some previous studies, including from South  
299 Asia, have examined the relation between COVID-19 vaccination or variants and commonly  
300 measured inflammatory and immunological markers.<sup>[10,18,19]</sup> Similar to our study, data from  
301 these previous reports suggest generally inverse associations between vaccination against  
302 COVID-19 and commonly measured inflammatory markers, and positive associations

303 between vaccination and immunological markers<sup>[10,18,19]</sup>. For example, an observational  
304 study conducted in Pakistan on a cohort of 434 COVID-19 patients reported significantly  
305 higher LDH, ferritin, and D-dimer levels in unvaccinated individuals compared to vaccinated  
306 individuals.<sup>[18]</sup> In another study comparing unvaccinated COVID-19 patients with the fully  
307 vaccinated group, significantly lower levels of IL-6 along with CRP and D-dimer were  
308 reported in the fully vaccinated group. This study also showed noticeably higher IgG in fully  
309 vaccinated individuals.<sup>[19]</sup> Similarly, significantly higher IgG levels among partially vaccinated  
310 individuals were also observed in our study.

311 Also corroborating our results, a recent observational study conducted in India on 1160  
312 hospitalized COVID-19 patients found similar trends of immunological and inflammatory  
313 biomarkers. This included raised D-Dimer levels reported after the first vaccination, but  
314 lower levels after 2 or 3 doses, and non-significant declining CRP.<sup>[10]</sup> Taken together with  
315 these previous data, the lower CRP, LDH, ferritin, D-dimer, Ang-2, and IL-6 inflammatory  
316 mediators among vaccinated individuals in our study add to the evidence that vaccine-  
317 induced protection with higher immunological mediators may help to reduce inflammation,  
318 which has been associated with more severe clinical outcomes in COVID-19.<sup>[20]</sup>

319 Previous evidence also suggests that the SARS-CoV-2 Omicron variant is less severe  
320 compared to other variants, and limited data from previous reports suggest that the  
321 Omicron variant may induce a smaller inflammatory and immune response.<sup>[8,21,22]</sup> The  
322 possible reasons noted are less effective replication in the lung parenchyma,<sup>[23]</sup> and  
323 sustained conservation of T-cell mediated immunity from previous infection or  
324 vaccination.<sup>[24]</sup> A study conducted in Australia assessed severity of COVID-19 variants  
325 through laboratory findings, and observed lower inflammatory markers, particularly ferritin,

326 LDH, and CRP levels, linked with Omicron variant compared to Delta variant. This study also  
327 found no significant differences in D-dimer levels.<sup>[8]</sup> A recent comparative study of the three  
328 waves of COVID-19 in India reported that infection with the Omicron variant versus Delta  
329 variant was associated with significantly lower levels of CRP and IL-6.<sup>[21]</sup> Another study  
330 conducted in Bangladesh reported higher levels of IgG, and higher risk of hospitalization and  
331 oxygen support were associated with infection with the Delta compared to Omicron  
332 variant.<sup>[22]</sup> Contributing to growing evidence suggesting that the Omicron variant is  
333 associated with less severe disease, our study also suggests that participants enrolled in  
334 waves of infection corresponding to the Omicron variant had lower inflammatory and  
335 immunological biomarkers.

336 Contrary to other inflammatory biomarkers, D-dimer concentration in our study was  
337 substantially higher in the third wave compared to the second wave participants. A study on  
338 D-dimer levels suggested that early management of infection with steroids and  
339 anticoagulants in the second wave may affect the production of D-dimer and limit the  
340 endothelial damage, however, only a few participants were on steroids and anticoagulants  
341 in our study.<sup>[25]</sup> Other reasons could be greater proportion of elderly individuals and high  
342 BMI reported in the third wave in our study which are independent risk factors of high D-  
343 dimer levels.<sup>[26,27]</sup> Importantly, we adjusted for these factors in analyses, suggesting that  
344 other unmeasured clinical factors may underlie the observed associations.

345 The immune response is a dynamic process that might also change the inflammatory  
346 parameters. Inflammatory response increases rapidly during the initial phase of infection  
347 and falls during the recovery period, therefore, longitudinal changes in inflammatory  
348 markers are more important rather than values of biomarkers at a single time point.<sup>[28]</sup>



349 Typically, after the onset of symptoms, immunological markers IgM and IgG can be detected  
350 during the first week and at around two weeks respectively,<sup>[29]</sup> and gradually these  
351 antibodies decline with time. The current study suggests that antibodies were higher among  
352 vaccinated participants who later became ill with COVID-19 compared with unvaccinated  
353 individuals. Particularly IgG antibodies remained high even after receiving two or three  
354 vaccine doses compared to those who did not receive any vaccine doses. Together with  
355 recent evidence from India indicating the effect of IgG levels on COVID-19-related measures  
356 such as viral emission<sup>[30]</sup> these findings help characterize the biological effects of COVID-19  
357 vaccination that may underlie disease severity and outcomes among SARS-CoV-2-infected  
358 individuals.

359 This study has a few limitations. Information on prior COVID-19 infection was not collected  
360 from the study participants which could affect in the vaccine-induced immune response and  
361 its impact on inflammatory biomarkers. Secondly, different types of COVID-19 vaccines can  
362 elicit diverse antibody responses, although in this study most (89%) of participants had  
363 received the adenoviral vector vaccine (COVISHIELD) in comparison to the whole cell  
364 inactivated virus (COVAXIN). Additionally, genome sequencing for confirmation of COVID-19  
365 variants was not performed in this study, and classification of two waves of the COVID-19  
366 pandemic was made based on defined time points by the federal COVID-19 task forces and  
367 previous research articles.<sup>[14]</sup> Therefore, there is the possibility that participants enrolled at  
368 beginning of the third wave may have been infected with either the Delta or the Omicron  
369 variant of the SARS-CoV-2 virus. Analyses were based on a small sample size, particularly for  
370 unvaccinated individuals in the third wave – which was likely due to good uptake of vaccines  
371 during the study period. This may have limited our ability to detect associations in certain  
372 cases, as evidenced by the wide confidence intervals for linear regression estimates.

373 Additionally, this study was based among individuals with mild-to-moderate COVID-19  
374 symptoms and no severe outcomes, meaning that we were unable to clearly examine the  
375 effect of vaccination status, wave of enrolment, and biomarker levels on clinical outcomes.

376 The foremost strength of this study is the diverse set of inflammatory and immunological  
377 biomarkers of COVID-19 infection explored, which gives an opportunity to understand the  
378 biological changes related to infection that are affected by prior COVID-19 vaccination and  
379 by SARS-CoV-2 variants. Furthermore, we were able to account for a range of potential  
380 demographic, clinical and health-related confounders by adjusting for these in final  
381 regression models. Changes in trends cross unadjusted and adjusted analyses suggested the  
382 importance of accounting for these characteristics when drawing conclusions regarding the  
383 potential effect of vaccination status and COVID-19 wave on biomarker levels. Additionally,  
384 this study also provides indicative data on the different clinical manifestations of two SARS-  
385 CoV-2 variants of concern. The study setting in India enables applicability of findings to the  
386 wider South Asia context where evidence on the effect of COVID-19 vaccine and SARS-CoV-2  
387 variants on inflammatory and immunological responses to SARS-CoV-2 infection remains  
388 scarce.

## 389 **Conclusion**

390 This study indicates that the inflammatory and immunologic response to SARS-CoV-2  
391 infection may be least partly associated with prior COVID-19 vaccination status and with the  
392 SARS-CoV-2 variant. This study provides data outlining potential pathways through which  
393 COVID-19 vaccination may protect against, and SARS-CoV-2 variants may influence, the  
394 likelihood of severe disease.

395

## 396 **References**

- 397 1. WHO. COVID-19 Weekly Epidemiological Update: Edition 122 Published 14 December  
398 2022. Geneva: World Health Organization; 2022.
- 399 2. Hong LZ, Shou ZX, Zheng DM, Jin X. The most important biomarker associated with  
400 coagulation and inflammation among COVID-19 patients. *Mol Cell Biochem*  
401 2021;476(7):2877–85.
- 402 3. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-  
403 CoV-2 variants, spike mutations and immune escape. *Nat Rev Microbiol*  
404 2021;19(7):409–24.
- 405 4. Davies MA, Kassanjee R, Rousseau P, Morden E, Johnson L, Solomon W, et al.  
406 Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth  
407 wave compared with previous waves in the Western Cape Province, South Africa. *Trop*  
408 *Med Int Health* 2022;27(6):564–73.
- 409 5. Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom  
410 prevalence, duration, and risk of hospital admission in individuals infected with SARS-  
411 CoV-2 during periods of omicron and delta variant dominance: a prospective  
412 observational study from the ZOE COVID Study. *The Lancet* 2022;399(10335):1618–24.
- 413 6. Ministry of Health and Family Welfare. CoWIN [Internet]. 2022 [cited 2023 Mar  
414 9]; Available from: <https://www.cowin.gov.in/>
- 415 7. Ministry of Health and Family Welfare. Cumulative Coverage Report of COVID-19  
416 Vaccination - 28 September 2022. New Delhi: Ministry of Health and Family Welfare,  
417 Government of India; 2022.
- 418 8. Wang J, Choy KW, Lim HY, Ho P. Laboratory markers of severity across three COVID-19  
419 outbreaks in Australia: has Omicron and vaccinations changed disease presentation?  
420 *Intern Emerg Med* 2023;18(1):43–52.
- 421 9. Brown PE, Fu SH, Bansal A, Newcombe L, Colwill K, Mailhot G, et al. Omicron BA.1/1.1  
422 SARS-CoV-2 Infection among Vaccinated Canadian Adults. *N Engl J Med*  
423 2022;386(24):2337–9.
- 424 10. Munigela A, Sowpati DT, M S, Banu S, Siva AB, V JK, et al. Clinical outcomes in  
425 individuals hospitalized with SARS-CoV-2 Delta variant (B.1.617.2) who had been  
426 vaccinated with Covishield (ChAdOx1) and Covaxin (BBV-152). *IJID Reg* 2022;5:104–10.
- 427 11. Sharma KK, Partap U, Mistry N, Marathe Y, Wang M, Shaikh S, et al. Randomised trial to  
428 determine the effect of vitamin D and zinc supplementation for improving treatment  
429 outcomes among patients with COVID-19 in India: trial protocol. *BMJ Open*  
430 2022;12(8):e061301.

- 431 12. MOHFW, GOI. Clinical Management Protocol for COVID-19 (In Adults) - Version 6  
432 (24.05.21) [Internet]. New Delhi: Ministry of Health and Family Welfare, Government  
433 of India; 2021 [cited 2022 Feb 28]. Available from:  
434 [https://www.mohfw.gov.in/pdf/UpdatedDetailedClinicalManagementProtocolforCOVI](https://www.mohfw.gov.in/pdf/UpdatedDetailedClinicalManagementProtocolforCOVID19adultsdated24052021.pdf)  
435 [D19adultsdated24052021.pdf](https://www.mohfw.gov.in/pdf/UpdatedDetailedClinicalManagementProtocolforCOVID19adultsdated24052021.pdf)
- 436 13. Indian Council for Medical Research, National Institute of Virology. Specimen  
437 Collection, Packaging and Transport Guidelines for 2019 novel Coronavirus (2019-  
438 nCoV) [Internet]. New Delhi: Ministry of Health and Family Welfare, Government of  
439 India; 2020 [cited 2023 Mar 9]. Available from:  
440 [https://www.mohfw.gov.in/pdf/5Sample%20collection\\_packaging%20%202019-](https://www.mohfw.gov.in/pdf/5Sample%20collection_packaging%20%202019-nCoV.pdf)  
441 [nCoV.pdf](https://www.mohfw.gov.in/pdf/5Sample%20collection_packaging%20%202019-nCoV.pdf)
- 442 14. Mahajan NN, Kesarwani S, Salunke C, Kumbhar P, Yenkure P, Shaikh J, et al. Clinical  
443 presentation, pregnancy complications, and outcomes of pregnant women with  
444 COVID-19 during the Omicron-dominant third wave in Mumbai, India. *Int J Gynecol*  
445 *Obstet* 2022;159(3):968–73.
- 446 15. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. *Cold Spring Harb*  
447 *Perspect Biol* 2009;1(6):a001651.
- 448 16. Bahl A, Johnson S, Maine G, Garcia MH, Nimmagadda S, Qu L, et al. Vaccination  
449 reduces need for emergency care in breakthrough COVID-19 infections: A multicenter  
450 cohort study. *Lancet Reg Health Am* 2021;4:100065.
- 451 17. Gupta N, Kaur H, Yadav PD, Mukhopadhyay L, Sahay RR, Kumar A, et al. Clinical  
452 Characterization and Genomic Analysis of Samples from COVID-19 Breakthrough  
453 Infections during the Second Wave among the Various States of India. *Viruses*  
454 2021;13(9):1782.
- 455 18. Fatima S, Zafar A, Afzal H, Ejaz T, Shamim S, Saleemi S, et al. COVID-19 infection among  
456 vaccinated and unvaccinated: Does it make any difference? *PloS One*  
457 2022;17(7):e0270485.
- 458 19. Wang C, Li Y, Pan Y, Zhou L, Zhang X, Wei Y, et al. Clinical and immune response  
459 characteristics among vaccinated persons infected with SARS-CoV-2 delta variant: a  
460 retrospective study. *J Zhejiang Univ Sci B* 2022;23(11):899–914.
- 461 20. Thwaites RS, Sanchez Sevilla Uruchurtu A, Siggins MK, Liew F, Russell CD, Moore SC, et  
462 al. Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-  
463 CSF in severe COVID-19. *Sci Immunol* 2021;6(57):eabg9873.
- 464 21. Singh S, Sharma A, Gupta A, Joshi M, Aggarwal A, Soni N, et al. Demographic  
465 comparison of the first, second and third waves of COVID-19 in a tertiary care hospital  
466 at Jaipur, India. *Lung India Off Organ Indian Chest Soc* 2022;39(6):525–31.
- 467 22. Ghosh AK, Landt O, Yeasmin M, Sharif M, Ratul RH, Molla MA, et al. Clinical  
468 Presentation of COVID-19 and Antibody Responses in Bangladeshi Patients Infected  
469 with the Delta or Omicron Variants of SARS-CoV-2. *Vaccines* 2022;10(11):1959.

- 470 23. Hui KPY, Ho JCW, Cheung MC, Ng KC, Ching RHH, Lai KL, et al. SARS-CoV-2 Omicron  
471 variant replication in human bronchus and lung ex vivo. *Nature* 2022;603(7902):715–  
472 20.
- 473 24. Choi SJ, Kim DU, Noh JY, Kim S, Park SH, Jeong HW, et al. T cell epitopes in SARS-CoV-2  
474 proteins are substantially conserved in the Omicron variant. *Cell Mol Immunol*  
475 2022;19(3):447–8.
- 476 25. Porfidia A, Porceddu E, Talerico R, Montalto M, Landi F, Pola R. Second wave of the  
477 COVID-19 pandemic: D-dimer levels are not so high anymore. *J Thromb Thrombolysis*  
478 2021;52(3):779–81.
- 479 26. Harper PL, Theakston E, Ahmed J, Ockelford P. D-dimer concentration increases with  
480 age reducing the clinical value of the D-dimer assay in the elderly. *Intern Med J*  
481 2007;37(9):607–13.
- 482 27. Tita-Nwa F, Bos A, Adjei A, Ershler WB, Longo DL, Ferrucci L. Correlates of D-dimer in  
483 older persons. *Aging Clin Exp Res* 2010;22(1):20–3.
- 484 28. Kim MJ, Lee EB, Song YW, Park JK. Profile of common inflammatory markers in  
485 treatment-naïve patients with systemic rheumatic diseases. *Clin Rheumatol*  
486 2020;39(10):2899–906.
- 487 29. Lau CS, Phua SK, Liang YL, Oh HML, Aw TC. Robust SARS-CoV-2 Antibody Responses in  
488 Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19  
489 Vaccine. *Vaccines* 2021;9(11):1241.
- 490 30. Sriraman K, Shaikh A, Vaswani S, Mestry T, Patel G, Sakthivel S, et al. Impact of COVID-  
491 19 vaccination on transmission risk of breakthrough infections: Lessons from adapted  
492 N95 mask sampling for emerging variants and interventions. *J Med Virol*  
493 2023;95(1):e28188.

494

495

496 **Tables**

**Table 1. Baseline characteristics of enrolled participants (N=181).**

N (%)	Overall (181)	COVID-19 Vaccination status				P	COVID -19 Waves		P
		Unvaccinated n=36	Partially vaccinated n=24	Fully vaccinated n=94	Missing n=27		Second wave n=120	Third wave n=61	
<b>Sex n (%)</b>									
Female	88 (48.6)	17(47.2)	12(50.0)	46(48.9)	13(48.1)	0.049	54(45.0)	34(55.7)	0.172
Male	93 (51.3)	19(52.8)	12(50.0)	48(51.1)	14(51.9)		66(55.0)	27(44.3)	
<b>Age, years, n (%)</b>									
18-29	30 (16.5)	5(13.9)	3(12.5)	13(13.8)	9(33.3)	0.008	19(15.8)	11(18.0)	0.381
30-44	55 (30.3)	18(50.0)	12(50.0)	19(20.2)	6(22.2)		41(34.2)	14(23.0)	
45-59	51 (28.1)	9(25.0)	5(20.8)	31(33.0)	6(22.2)		30(25.0)	21(34.4)	
≥60	45 (24.8)	4(11.1)	4(16.7)	31(33.0)	6(22.2)		30(25.0)	15(24.6)	
<b>Education, n (%)</b>									
Illiterate, no formal, Primary	15 (8.2)	8(22.2)	1(4.2)	3(3.2)	3(11.1)	0.006	15(12.5)	0(0.0)	0.004
Secondary or senior secondary	54 (29.8)	8(22.2)	5(20.8)	34(36.2)	7(25.9)		36(30.0)	18(29.5)	
Graduate	65 (35.9)	8(22.2)	12(50.0)	36(38.3)	9(33.3)		36(30.0)	29(47.5)	
Post-graduate	45 (24.8)	12(33.3)	6(25.0)	19(20.2)	8(29.6)		32(26.7)	13(21.3)	
Missing	2 (1.1)	0(0.0)	0(0.0)	2(2.1)	0(0.0)		1(0.8)	1(1.6)	
<b>Health Behaviour, n (%)</b>									
Smoking	8 (4.4)	2(5.6)	0(0.0)	5(5.3)	1(3.7)	0.736	7(5.8)	1(1.6)	0.270
Current alcohol use (n=180)	19 (10.6)	2(5.6)	3(12.5)	13(14.0)	1(3.7)	0.427	10(8.33)	9(14.75)	0.189
Missing alcohol (n=1)	1(0)	0(0.0)	0(0.0)	1(1.06)	0(0.0)		1(0.83)	0(0)	
<b>Pre-existing conditions, n (%)</b>									
Hypertension	45 (24.8)	4(11.1)	4(16.7)	31(33.0)	6(22.2)	0.023	28(23.3)	17(27.9)	0.505

**Table 1. Baseline characteristics of enrolled participants (N=181).**

N (%)	Overall (181)	COVID-19 Vaccination status				P	COVID -19 Waves		P
		Unvaccinated n=36	Partially vaccinated n=24	Fully vaccinated n=94	Missing n=27		Second wave n=120	Third wave n=61	
Diabetes	38 (20.9)	9(25.0)	3(12.5)	22(23.4)	4(14.8)	0.472	26(21.7)	12(19.7)	0.755
Heart disease	14 (7.7)	3(8.3)	1(4.2)	7(7.5)	3(11.1)	0.911	11(9.2)	3(4.9)	0.389
Asthma	7 (3.8)	2(5.6)	0(0.0)	4(4.3)	1(3.7)	0.605	4(3.3)	3(4.9)	0.689
Neurological conditions	4 (2.2)	1(2.8)	0(0.0)	0(0.0)	3(11.1)	0.390	3(2.5)	1(1.6)	1.000
Chronic kidney disease	3 (1.6)	2(5.6)	0(0.0)	1(1.1)	0(0.0)	0.200	2(1.7)	1(1.6)	1.000
Chronic obstructive pulmonary disease	1 (0.5)	1(2.8)	0(0.0)	0(0.0)	0(0.0)	0.390	1(0.8)	0(0.0)	1.000
Other (Thyroid ,TB , cancer etc)	8 (4.4)	3(8.3)	1(4.2)	2(2.1)	2(7.4)	0.131	6(5.0)	2(3.3)	0.719
Any pre-existing condition	72 (39.7)	13(36.1)	7(29.2)	43(45.7)	9(33.3)	0.270	49(40.8)	23(37.7)	0.684
<b>COVID-19 medication, n (%)</b>									
Favipiravir	3 (1.6)	1(2.8)	0(0.0)	2(2.1)	0(0.0)	1.000	3(2.5)	0(0.0)	0.552
Remdesivir	22(12.2)	1(2.8)	4(16.7)	15(16.0)	2(7.4)	0.101	16(13.3)	6(9.8)	0.496
Dexamethasone	1 (0.5)	0(0.0)	0(0.0)	1(1.1)	0(0.0)	1.000	1(0.8)	0(0.0)	1.000
Monoclonal antibodies	8 (4.4)	1(2.8)	2(8.3)	5(5.3)	0(0.0)	0.765	8(6.7)	0(0.0)	0.053
Molnupiravir	5 (2.8)	0(0.0)	1(4.2)	4(4.3)	0(0.0)	0.541	0(0.0)	5(8.2)	0.004
Clexan	1 (0.5)	0(0.0)	0(0.0)	1(1.1)	0(0.0)	1.000	0(0.0)	1(1.6)	0.337
Any COVID-19 Medication	36 (19.8)	3(8.3)	7(29.2)	24(25.5)	2(7.4)	0.061	25(20.8)	11(18.0)	0.655
<b>BMI (kg/m<sup>2</sup>), n (%)</b>									
<18.5	6 (3.3)	1(2.8)	2(8.3)	2(2.1)	1(3.7)		4(3.3)	2(3.3)	
18.5-24.9	63 (34.8)	13(36.1)	9(37.5)	29(30.9)	12(44.4)	0.473	46(38.3)	17(27.9)	0.019
25-29.9	56 (30.9)	13(36.1)	6(25.0)	26(27.7)	11(40.7)		42(35.0)	14(23.0)	



**Table 1. Baseline characteristics of enrolled participants (N=181).**

N (%)	Overall (181)	COVID-19 Vaccination status				P	COVID -19 Waves		P
		Unvaccinated n=36	Partially vaccinated n=24	Fully vaccinated n=94	Missing n=27		Second wave n=120	Third wave n=61	
≥30	56 (30.9)	9(25.0)	7(29.2)	37(39.4)	3(11.1)		28(23.3)	28(45.9)	
<b>Median number of days with symptoms (IQR)</b>	3 (2-4)	3(2-5)	3(2-5)	2(2-3)	4(2-6)	0.154	3 (2-5)	2 (2-3)	0.105
<b>COVID-19 waves during enrolment, n (%)</b>									
Second wave <sup>1</sup>	120 (66.3)	35(97.2)	19(79.2)	40(42.6)	26(96.3)	<0.001	-		
Third wave <sup>1</sup>	61 (33.7)	1(2.8)	5(20.8)	54(57.5)	1(3.7)				
<b>COVID-19 vaccination status, n (%)</b>									
Unvaccinated	36(19.9)						35(29.2)	1(1.6)	
First Dose	24(13.3)	--					19(15.8)	5(8.2)	<0.001
Second /Booster dose	94(51.9)						40(33.3)	54(88.5)	
Missing	27(14.9)						26(21.7)	1(1.6)	
<b>Median days of last vaccine dose before enrolment (IQR) (n=118)</b>	126 (51-216)	-	61 (31-92)	167 (77-241)	-	<0.001	85 (45-169)	201 (111-274)	<0.001
<b>COVID-19 vaccine type n (%)</b>									
Covishield (AstraZeneca and SII)	105 (58.1)	-	22(91.7)	83(88.3)	-		50(41.7)	55(90.2)	
Covaxin (Bharat Biotech)	13 (7.1)	-	2(8.3)	11(11.7)	-	0.482	9 (7.5)	4(6.6)	0.119
Unvaccinated at enrolment	36 (19.9)	36 (100)	-	-	-		35 (29.1)	1(1.6)	
Missing	27(14.9)	-	-	-	27(100.0)		26(21.7)	1(1.6)	

Unvaccinated: received no doses of COVID-19 vaccine. Partially vaccinated: received 1 dose of COVID-19 vaccine. Fully vaccinated: received 2 or 3 doses of COVID-19 vaccine.

Differences between categories were tested using Pearson's Chi-squared tests (Fisher's exact tests for cell count < 5) for categorical variables and Wilcoxon rank sum tests used for continuous variables.

The second wave of the COVID-19 pandemic in India was defined as the period spanning approximately April 2021 (when study enrolment began) to December 15<sup>th</sup>, 2021. The third wave was defined as the period spanning from December 21<sup>st</sup>, 2021, onwards.

**Table 2. Median (interquartile range) levels of inflammatory and immunological biomarkers overall and across participant characteristics.**

	Inflammatory markers					Immunological markers			
	CRP (mg/L) (N=176)	LDH (IU/L) (N=154)	Serum Ferritin (ng/ml) (N=160)	D-dimer (ng/ml) (N=168)	IL-6 (pg/ml) (N=178)	Ang-2 (pg/ml) (N=178)	sTREM-1 (pg/ml) (N=48)	IgM (U/mL) (N=177)	IgG (U/mL) (N=177)
<b>Overall median, IQR</b>	13.4 (5.0-34.6)	244 (199-321)	153 (61-311)	426 (291-670)	5.1 (2.7-10.5)	1,198 (848-1,690)	148 (66-148)	3.1 (1.1-7.0)	7.1 (0.6-86.8)
<b>Vaccination status</b>									
Unvaccinated	24.1 (5.4-50.6)	290 (220-342)	215 (124-490)	450 (319-718)	9.0 (4.0-13.7)	1,012 (770-1,703)	144 (27-188)	3.3 (1.3-5.9)	1.2 (0.4-98.3)
Partially Vaccinated	14.1 (5.6-39.6)	297 (217-338)	112 (65-515)	475 (288-768)	5.1 (2.5-9.0)	1,226 (933-1,544)	145 (68-169)	5.4 (1.7-14.2)	31.2 (5.3-165.5)
Fully Vaccinated	12.2 (4.6-34.9)	225 (186-274)	124 (43-215)	372 (274-573)	4.3 (2.3-7.4)	1,238 (913-1,646)	150 (23-283)	1.9 (0.8-4.9)	7.5 (1.0-63.5)
<b>P</b>	<b>0.504</b>	<b>&lt;0.001</b>	<b>0.005</b>	<b>0.202</b>	<b>&lt;0.001</b>	<b>0.454</b>	<b>0.977</b>	<b>0.014</b>	<b>0.009</b>
<b>COVID-19 wave</b>									
Second wave <sup>2</sup>	16.2 (5.4-50.6)	271 (205-337)	194 (102-461)	468 (288-744)	6.1 (2.2-10.7)	1,130 (767-1,736)	148 (66-184)	5.3 (2.2-10.7)	13.8 (1.0-110.9)
Third wave <sup>3</sup>	9.9 (4.5-26.0)	225 (191-276)	101 (32-169)	381 (296-515)	4.1 (0.5-2.3)	1,286 (1,000-1,590)	-	1.4 (0.5-2.3)	3.2 (0.5-16.5)
<b>P</b>	<b>0.028</b>	<b>0.014</b>	<b>&lt;0.001</b>	<b>0.155</b>	<b>0.008</b>	<b>0.322</b>	-	<b>&lt;0.001</b>	<b>0.019</b>

Unvaccinated: received no doses of COVID-19 vaccine. Partially vaccinated: received 1 dose of COVID-19 vaccine. Fully vaccinated: received 2 or 3 doses of COVID-19 vaccine.

IQR: interquartile range.

Unadjusted medians (IQR) are reported for all biomarkers (please refer to Tables 3 and 4 for adjusted analyses).

P values are based on Wilcoxon's rank sum test (2 groups), or Kruskal Wallis test (multiple groups).

The second wave of the COVID-19 pandemic in India was defined as the period spanning approximately April 2021 (when study enrolment began) to December 15th, 2021. The third wave was defined as the period spanning from December 21st, 2021, onwards.

**Table 3. Estimates of association between COVID-19 vaccination status and inflammatory and immunological biomarkers.**

	<b>β Coefficient (95% Conf. Interval)</b>	<b>P</b>
<b>CRP (mg/L)</b>		
Partially vaccinated	-26.1 (-102.1-50.0)	0.502
Fully Vaccinated	-28.5 (-88.0-30.9)	0.347
<b>LDH (IU/L)</b>		
Partially vaccinated	9.3 (-31.7-50.2)	0.658
Fully Vaccinated	-77.4 (-89.3--65.4)	<0.001
<b>Serum Ferritin (ng/ml)</b>		
Partially vaccinated	-38.7 (-439.6-362.2)	0.850
Fully Vaccinated	-177.4 (-691.3-336.5)	0.499
<b>D-Dimer (ng/ml)</b>		
Partially vaccinated	95.4 (-450.3-641.2)	0.732
Fully Vaccinated	-248.9 (-1,009.4-511.7)	0.521
<b>IL-6 (pg/ml)</b>		
Partially vaccinated	-41.8 (-81.7--1.9)	0.040
Fully Vaccinated	-36.3 (-81.4-8.9)	0.116
<b>Angiotensin-2 (pg/ml)</b>		
Partially vaccinated	1.5 (-379.9-382.9)	0.994
Fully Vaccinated	-61.0 (-121.0--1.0)	0.046
<b>sTREM-1 (pg/ml)</b>		
Partially vaccinated	16.5 (-91.4-124.3)	0.765
Fully Vaccinated	72.6 (70.6-74.5)	<0.001
<b>IgM (U/mL)</b>		
Partially vaccinated	52.7 (-145.7-251.0)	0.603
Fully Vaccinated	-13.9 (-43.6-15.9)	0.360
<b>IgG (U/mL)</b>		
Partially vaccinated	61.5 (48.9-74.1)	<0.001
Fully Vaccinated	62.2 (56.7-67.6)	<0.001

Unvaccinated: received no doses of COVID-19 vaccine. Partially vaccinated: received 1 dose of COVID-19 vaccine. Fully vaccinated: received 2 or 3 doses of COVID-19 vaccine.

95% CI: 95% confidence interval.

Estimates based on mixed effect regression models with robust standard errors.

The comparison group in the model is unvaccinated participants.

The model is adjusted for wave enrolled, age, gender, type of vaccine, BMI, COVID medications, pre-existing diseases, days of symptoms, health behaviour (drinking and smoking), and clustered by hospital sites.

499

500

501

**Table 4. Estimates of association between COVID -19 waves and inflammatory and immunological biomarkers.**

	$\beta$ Coefficient (95% Conf. Interval)	P
<b>CRP (mg/L)</b>		
Enrolled wave 3	-21.7 (-44.0-0.6)	0.056
<b>LDH (IU/L)</b>		
Enrolled wave 3	-14.4 (-30.8-1.9)	0.084
<b>Serum ferritin (ng/ml)</b>		
Enrolled wave 3	-29.1 (-171.1-112.9)	0.688
<b>D-Dimer (ng/ml)</b>		
Enrolled wave 3	322.5 (80.9-564.2)	0.009
<b>IL-6 (pg/ml)</b>		
Enrolled wave 3	-12.0 (-12.6--11.4)	<0.001
<b>Angiotensin-2 (pg/ml)</b>		
Enrolled wave 3	-26.5 (-139.1-86.0)	0.644
<b>sTREM-1 (pg/ml)</b>		
Enrolled wave 3	--	--
<b>IgM (U/mL)</b>		
Enrolled wave 3	-23.6 (-42.3--4.9)	0.013
<b>IgG (U/mL)</b>		
Enrolled wave 3	-77.6 (-99.4--55.8)	<0.001

95% CI: 95% confidence interval.

Estimates based on mixed effects regression models with robust standard errors

The comparison group is wave 2 participants

The model is adjusted for age, gender, vaccination status (unvaccinated: 0 doses of COVID-19 vaccine, partially vaccinated: 1 dose, fully vaccinated: 2 or 3 doses) and type of vaccine, BMI, COVID medications, pre-existing diseases, days of symptoms, health behaviour (drinking and smoking), and clustered by hospital sites.

The second wave of the COVID-19 pandemic in India was defined as the period spanning approximately April 2021 (when study enrolment began) to December 15th, 2021. The third wave was defined as the period spanning from December 21st, 2021, onwards.

502

503